Venus Remedies share news and announcements
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,404.30down ₹37.20 (2.58%)BSE ₹1,396.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,441.50.
52-week range of traded prices to 23 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,877 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 Jul 2026
- 16.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 2.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 Jul 2026
- 19.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 Jul 2026
- 21.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day.
- 52,800
Venus Remedies routine notices
118 filed, newest first. Page 2 of 3.
Jan 2024
10 Jan · Routine
Dec 2023
21 Dec · Routine
7 Dec · Routine
Nov 2023
11 Nov · Routine
Sep 2023
26 Sep · Routine
23 Sep · Routine
Aug 2023
16 Aug · Routine
Jul 2023
24 Jul · Routine
22 Jul · Routine
17 Jul · Routine
Jun 2023
May 2023
31 May · Routine
17 May · Routine
Mar 2023
Feb 2023
22 Feb · Routine
2 Feb · Routine
Dec 2022
Nov 2022
Sep 2022
Aug 2022
17 Aug · Routine
Jul 2022
30 Jul · Routine
1 Jul · Routine
Jun 2022
Apr 2022
19 Apr · Routine
Mar 2022
31 Mar · Routine
15 Mar · Routine
Feb 2022
1 Feb · Routine
Jan 2022
Dec 2021
7 Dec · Routine
Nov 2021
1 Nov · Routine
Oct 2021
29 Oct · Routine
19 Oct · Routine
Sep 2021
2 Sep · Routine
Aug 2021
19 Aug · Routine
14 Aug · Routine
13 Aug · Routine
Jul 2021
16 Jul · Routine
Jun 2021
Mar 2021
Feb 2021
10 Feb · Routine
1 Feb · Routine